Potential strategy for the therapeutic regulation of the endocannabinoid system with interfering peptides that modulate SGIP1 binding
Alexandra Fletcher-Jones, Ellen Spackman, Bram Mylemans, Tim J. Craig, Yasuko Nakamura, Kevin A. Wilkinson, Derek N. Woolfson, Jeremy M. Henley · FENS Forum 2024
There is intense scientific, medical, and societal interest in the endocannabinoid system (ECS) because it modulates a wide range of brain functions including mood, appetite/energy expenditure, and learning and memory. However, because of the complex and pleotropic pharmacology of the ECS, cannabinoid drugs are associated with unwanted neurological and psychoactive side effects. These limitations drive the need for increased biochemical and cell biological understanding of the ECS and a reappraisal of how this system may be targeted therapeutically.Endocannabinoid signalling mediated by cannab
ePoster · Neuroscience